RxDoctor Payments Data

Atulkumar Patel, MD

Interventional Cardiology · Edmond, OKNPI 1699779249

Payments from drug & device makers

$536in general payments, 2019–2025

Across 19 payments — averaging $28.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$346
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$66
  • Kestra Medical Technology Services, Inc.$39
  • Amgen$31
  • Otsuka America Pharmaceutical, Inc.$25
  • AstraZeneca$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$536100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$536 in reported general payments places this provider in the 5th percentile of 110 interventional cardiology providers in Oklahoma.

See all interventional cardiology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$139,325
Medicare patients
2,873
Services billed
4,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban513$410,397
XareltoRivaroxaban82$76,483
Repatha SureclickEvolocumab72$56,962
JardianceEmpagliflozin49$32,486
BrilintaTicagrelor37$23,957
Prasugrel Hcl71$4,851
Ranolazine ErRanolazine69$4,283
ClopidogrelClopidogrel Bisulfate309$4,112
Telmisartan154$3,881
Metoprolol Succinate267$3,568
Atorvastatin Calcium293$3,455
Rosuvastatin Calcium233$3,154
Amlodipine Besylate374$2,969
Lisinopril410$2,815
Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid39$2,628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$15$23,95737 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 110 interventional cardiology providers in Oklahoma.

Other interventional cardiology in Edmond

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →